A Clinical Study Evaluating the Safety and Efficacy of the VCFix Spinal System for Treatment of Vertebral Compression Fractures. (EXPAND)

Amber Implants B.V.

Status: Enrolling

Conditions: Vertebral Compression Fracture

Treatments: Device: VCFix Spinal System in stand-alone configuration

Study type: Interventional

Funder types: Industry

Identifiers

NCT07301749

CIP-VS02-EU

Details and patient eligibility

About

The primary objective of the EXPAND clinical investigation is to evaluate the safety and efficacy of the VCFix Spinal System for the treatment of Vertebral Compression Fractures. The study aims to demonstrate a reduction in vertebral fracture-related pain and an improvement in physical function and mobility, while ensuring the absence of (serious) adverse events ((S)AE) related to the device or procedure.

Enrollment: 103 estimated patients

Sex: All

Ages: 21 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subject is ≥ 21 to ≤ 85 years old.

2. Single vertebral fracture which meets all of the following criteria:

   • Type A fractures from AO spine classification (compression injuries);
   • Vertebral fracture located in the thoracic and lumbar regions of the spine
   • Fracture age < 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
   • Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence
   • Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery

3. Subject has a NPRS back pain score of ≥5

4. Subject is a candidate for surgical intervention based on investigator opinion

5. Subject has a body Mass Index (BMI) < 35

6. Subject is mentally capable of complying with trial protocol requirements for the duration of the study

7. Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent

Exclusion criteria

1. Neoplasms with posterior involvement and/or presence of a mass within the spinal canal

2. Non-mobile fractures (i.e., fracture is not recent (>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction).

3. Spondylolisthesis > Grade 1 at target vertebral body(s)

4. Local kyphotic angle > 30°

5. Pre-existing vertebral fracture prior to the index fracture

6. Subjects that require anterior stabilization of the index fracture

7. Fracture to the pedicle based on radiographic evaluation

8. Spinal cord compression or canal compromise requiring decompression

9. Severe back pain due to causes other than acute fracture with NPRS score>5

10. The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)

11. Pain due to any other condition that requires daily narcotic (opiates or opioids) medication

12. Pre-existing neurological deficit, radiculopathy or myelopathy

13. Pre-existing condition or significant co-morbidity:

    • Uncontrolled diabetes (HbA1c >8%)
    • Severe cardiopulmonary deficiencies
    • Any other condition that would impact study outcome in the opinion of the investigator

14. Contraindications to both MRI and radionuclide bone scan

15. Concurrent participation in another clinical study which could potentially interfere with the outcome of this study.

16. A life expectancy less than the study duration or undergoing palliative care

17. Subject non-ambulatory prior to fracture

18. Allergy to any components of the device/instruments used during the procedure

19. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection

20. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.)

21. Any evidence of alcohol or drug abuse.

22. Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for >3 months)

23. The subject is currently on anti-cancer therapy or anti-HIV therapy

24. Pregnancy or subjects with child-bearing potential that are unwilling to use contraception throughout the study duration

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

103 participants in 1 patient group

VCFix Spinal System

Experimental group

Treatment:

Device: VCFix Spinal System in stand-alone configuration